Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Aggressive Growth Stocks
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Insurance Industry Stock Outlook - May 2013
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- AWS 5/22: Will Bernanke Show His Hand?
- PFP 5/22: Singular Stock Focus Continues
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/22/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 12.64% |
| TRI TECH HOL | TRIT | 8.82% |
| SONIC FOUNDR | SOFO | 7.78% |
| A M R CP | AAMRQ | 8.29% |
| DIXIE GROUP | DXYN | 7.16% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
AptarGroup, Inc. ( ATR - Snapshot Report ) has completed the acquisition of Stelmi Group, thereby expanding its offerings in the pharmaceutical industry. The company has also lowered its guidance for the second quarter.
In May this year, the company had signed an agreement to acquire France-based Stelmi for approximately 165 million euros ($207 million). Stelmi makes elastomer primary packaging components used for injectable drugs. It operates two manufacturing plants located in the Normandy region of France and has a Research and Development center near Paris.
In 2011, Stelmi generated revenues of 83 million euros ($104 million) and earnings before interest, taxes, depreciation and amortization (EBITDA) margins in the range of 21-25% over the past 3 years.
AptarGroup for its part lowered the fiscal 2012 second quarter earnings per share guidance to a range of 60 cents to 62 cents from the previous guidance of 70 cents to 75 cents. This is to reflect acquisition costs of 5 cents per share related to the Stelmi acquisition as well as weak sales volume in the company’s European operations and strengthening of the U.S. dollar compared to the Euro (a negative impact of 2 cents per share). The Zacks Consensus Estimate for the quarter is currently pegged at 67 cents.
The Stelmi acquisition fits with Aptar’s strategy to enter new markets and applications, and to look for opportunities in the pharmaceutical and biotech industries. This acquisition marks Aptar’s foray in a new area of primary packaging components used in the injectable drug delivery market.
Crystal Lake, Illinois-based AptarGroup supplies a broad range of innovative dispensing systems for the fragrance/cosmetic, personal care, pharmaceutical, household and food/beverage markets worldwide. The company has its manufacturing facilities in North America, Europe, Asia and South America. It competes with Amcor Ltd. ( AMCRY ) and Rexam plc ( REXMY ) . The stock currently has a Zacks #3 Rank (short-term Hold recommendation).
Read the full Snapshot Report on ATR
Read the full on REXMY
Read the full on AMCRY